Protocol No.: EFT508-0011

Title
Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-L1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-L1 Therapy
Principal Investigator
Almubarak, Mohammed
Phase
II
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Carla Ross, RN
Senior Research Nurse
Phone: +1 304-293-2633

View on ClinicalTrials.gov